Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours

被引：0
|
作者：
Daniel M. Huse
Margaret von Mehren
Gregory Lenhart
Heikki Joensuu
Charles Blanke
Weiwei Feng
Stan Finkelstein
George Demetri
机构：
[1] Thomson Medstat,Department of Medical Oncology
[2] Fox Chase Cancer Center,Department of Oncology, Helsinki University
[3] Helsinki University Central Hospital,MIT Sloan School of Management
[4] The Oregon Health and Science University Cancer Institute,Dana
[5] Novartis Pharmaceuticals Corporation,Farber Cancer Institute
[6] Oncology,undefined
[7] Harvard-MIT Division of Health Sciences and Technology,undefined
[8] Center for Sarcoma and Bone Oncology,undefined
来源：
Clinical Drug Investigation | 2007年 / 27卷
关键词：
Pancreatic Cancer; Imatinib; National Comprehensive Cancer Network; National Comprehensive Cancer Network; Imatinib Mesylate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is partly dependent on reimbursement by third-party payers in many countries. The objective of this study was to estimate the cost effectiveness of imatinib mesylate in the treatment of GIST.
引用
收藏
页码：85 / 93
页数：8
相关论文
共 50 条
  • [41] Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor
    Trent, Jonathan C.
    Dupart, Jheri
    Zhang, Wei
    CURRENT CANCER THERAPY REVIEWS, 2005, 1 (01) : 93 - 108
  • [42] Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate
    Sith Phongkitkarun
    Cholada Phaisanphrukkun
    Janjira Jatchavala
    Ekaphop Sirachainan
    World Journal of Gastroenterology, 2008, (06) : 892 - 898
  • [43] Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate
    Phongkitkarun, Sith
    Phaisanphrukkun, Cholada
    Jatchavala, Janjira
    Sirachainan, Ekaphop
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (06) : 892 - 898
  • [44] Treatment of localized anorectal gastrointestinal stromal tumors with preoperative imatinib mesylate therapy
    Wang, W.
    Luo, S.
    Chen, W.
    Kang, L.
    Deng, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S412 - S412
  • [45] Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
    Ksienski, Doran
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 365 - 379
  • [46] Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST).
    Gronchi, A
    Fiore, M
    Bertulli, R
    Colecchia, M
    Tamborini, E
    Pilotti, S
    Messina, A
    Coco, P
    Stacchiotti, S
    Casali, PG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 825S - 825S
  • [47] Use of imatinib mesylate in a cat with gastrointestinal stromal tumour
    Won, Sungjun
    Kim, Yongbaek
    Yoon, Junghee
    VETERINARY RECORD CASE REPORTS, 2019, 7 (01):
  • [48] Approval Summary: Imatinib Mesylate in the Adjuvant Treatment of Malignant Gastrointestinal Stromal Tumors
    Cohen, Martin H.
    Cortazar, Patricia
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (03): : 300 - 307
  • [49] KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    Debiec-Rychter, Maria
    Sciot, Raf
    Le Cesne, Axel
    Schlemmer, Marcus
    Hohenberger, Peter
    van Oosterom, Allan T.
    Blay, Jean-Yves
    Leyvraz, Serge
    Stul, Michel
    Casali, Paolo G.
    Zalcberg, John
    Verweij, Jaap
    Van Glabbeke, Martine
    Hagemeijer, Anne
    Judson, Ian
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) : 1093 - 1103
  • [50] Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib
    Gunhild Mechtersheimer
    Gerlinde Egerer
    Manfred Hensel
    Ralf J. Rieker
    Martin Libicher
    Thomas Lehnert
    Roland Penzel
    Virchows Archiv, 2004, 444 : 108 - 118
12345